RxSight Taps Aziz Mottiwala as CEO, Succeeding Founder Ron Kurtz; New Chief Lands $14M Equity Grant
RXST sits 17% above its 52-week low of $4.48.
Summary
RxSight appointed Aziz Mottiwala as CEO, replacing founder Ron Kurtz, who transitions to Chief Medical Officer. The new CEO receives a $14 million equity grant, and the company adopted a new inducement plan with 3.5 million shares reserved.
Key Events · Executive and Board Changes · RXST
-
CEO Transition
Effective July 20, 2026, Aziz Mottiwala steps in as President and CEO, taking the reins from founder Ron Kurtz, M.D., who moves into the Chief Medical Officer role.
-
New CEO Compensation
Mottiwala's package includes a $750,000 base salary, a 90% target bonus, and a $14 million equity grant—split into $2M in options and $12M in RSUs—under the newly adopted 2026 Inducement Plan.
-
Founder Retention Package
Kurtz retains a $740,000 base salary and a 100% target bonus, plus up to $1.48M in retention bonuses and a 500,000-share RSU grant that vests through 2028.
-
New Inducement Plan
The board adopted the 2026 Inducement Equity Incentive Plan, reserving 3.5 million shares for new hire grants, which introduces additional dilution.
Analysis · RXST · Industrial Applications And Services
In a move that signals a strategic pivot toward scaling sales, RxSight is replacing its founder-CEO with a commercial leader who brings deep eye-care experience. The incoming chief, Aziz Mottiwala, secures a $14 million equity package—$2 million in options and $12 million in RSUs—a substantial commitment for a company valued at $217 million. Meanwhile, founder Ron Kurtz will remain as Chief Medical Officer, supported by a 500,000-share RSU grant and retention bonuses. Adding potential dilution, the board also adopted a new inducement plan with 3.5 million shares reserved. This leadership overhaul arrives just days after the company unveiled a major Alcon collaboration and cut full-year guidance, suggesting the board is seeking a new commercial strategy to reverse the revenue decline.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RXST was trading at $5.25 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $217.3M. The 52-week trading range was $4.48 to $13.22. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.